{"contacts": [{"terms": [{"accession": "MS:1002037", "name": "dataset submitter"}, {"accession": "MS:1000586", "name": "contact name", "value": "Jennifer Abelin"}, {"accession": "MS:1000589", "name": "contact email", "value": "jabelin@neontherapeutics.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Neon Therapeutics"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Jennifer Abelin"}, {"accession": "MS:1000589", "name": "contact email", "value": "jabelin@neontherapeutics.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Neon Therapeutics"}]}], "description": "Increasing evidence indicates CD4+ T cells can recognize cancer-specific antigens and control tumor growth. However, it remains difficult to predict the antigens that will be presented by human leukocyte antigen class II molecules (HLA-II) - hindering efforts to optimally target them therapeutically. Obstacles include inaccurate peptide-binding prediction and unsolved complexities of the HLA-II pathway. To address these challenges, we introduce an improved technology for discovering HLA-II binding motifs and conduct a comprehensive analysis of tumor-ligandomes to learn processing rules relevant in the tumor microenvironment (TME). We profiled HLA-II alleles and showed that binding motifs are highly sensitive to HLA-DM, a peptide loading chaperone. We also revealed that intratumoral HLA-II presentation is dominated by professional antigen presenting cells (APCs), rather than cancer cells. Integrating these observations, we developed algorithms that accurately predict APC ligandomes, including peptides from phagocytosed cancer cells. These tools and biological insights will enhance HLA-II directed cancer therapies.", "fullDatasetLinks": [{"accession": "MS:1002488", "name": "MassIVE dataset URI", "value": "http://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=1cda619f219542f380130d7204fdb240"}, {"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://massive.ucsd.edu/MSV000083991/"}], "identifiers": [{"accession": "MS:1002487", "name": "MassIVE dataset identifier", "value": "MSV000083991"}, {"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD014293"}, {"accession": "MS:1001921", "name": "ProteomeXchange accession number version number", "value": "1"}], "instruments": [{"accession": "MS:1002732", "name": "Orbitrap Fusion Lumos"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "hla, epitope, prediction, classii, neoantigen"}], "modifications": [{"accession": "UNIMOD:312", "name": "Cysteinyl"}, {"accession": "UNIMOD:35", "name": "Oxidation"}, {"accession": "UNIMOD:28", "name": "Gln->pyro-Glu"}, {"accession": "UNIMOD:4", "name": "Carbamidomethyl"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "31495665"}, {"accession": "MS:1002866", "name": "Reference", "value": "Abelin JG, Harjanto D, Malloy M, Suri P, Colson T, Goulding SP, Creech AL, Serrano LR, Nasir G, Nasrullah Y, McGann CD, Velez D, Ting YS, Poran A, Rothenberg DA, Chhangawala S, Rubinsteyn A, Hammerbacher J, Gaynor RB, Fritsch EF, Greshock J, Oslund RC, Barthelme D, Addona TA, Arieta CM, Rooney MS. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. Immunity. Epub 2019 Aug 31."}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens"}, {"accession": "MS:1001468", "name": "taxonomy: common name", "value": "human"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction"}